BioXcel Therapeutics, Inc. (BTAI)
0.0739
-0.04
(-37.11%)
USD |
NASDAQ |
Sep 04, 16:00
0.0434
-0.03
(-41.27%)
After-Hours: 20:00
BioXcel Therapeutics Total Assets (Quarterly) : 28.80M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 28.80M |
| March 31, 2026 | 34.02M |
| December 31, 2025 | 47.52M |
| September 30, 2025 | 44.79M |
| June 30, 2025 | 25.79M |
| March 31, 2025 | 38.57M |
| December 31, 2024 | 38.34M |
| September 30, 2024 | 48.89M |
| June 30, 2024 | 65.44M |
| March 31, 2024 | 82.32M |
| December 31, 2023 | 73.70M |
| September 30, 2023 | 100.45M |
| June 30, 2023 | 140.10M |
| March 31, 2023 | 180.10M |
| December 31, 2022 | 205.85M |
| September 30, 2022 | 244.82M |
| June 30, 2022 | 248.24M |
| March 31, 2022 | 211.04M |
| December 31, 2021 | 239.44M |
| September 30, 2021 | 261.33M |
| Date | Value |
|---|---|
| June 30, 2021 | 281.11M |
| March 31, 2021 | 200.39M |
| December 31, 2020 | 219.94M |
| September 30, 2020 | 238.75M |
| June 30, 2020 | 70.46M |
| March 31, 2020 | 85.81M |
| December 31, 2019 | 36.39M |
| September 30, 2019 | 43.70M |
| June 30, 2019 | 34.28M |
| March 31, 2019 | 40.33M |
| December 31, 2018 | 43.55M |
| September 30, 2018 | 47.87M |
| June 30, 2018 | 51.21M |
| March 31, 2018 | 56.32M |
| December 31, 2017 | 1.355M |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | 0.007M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | 183.47M |
| Agenus, Inc. | 172.69M |
| Amgen, Inc. | 95.64B |
| BioCryst Pharmaceuticals, Inc. | 557.85M |
| Imunon, Inc. | 14.99M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 144.26M |
| Shareholders Equity (Quarterly) | -115.46M |
| Debt to Equity Ratio | -0.9047 |
| Current Ratio | 0.2093 |
| Net Debt Paydown Yield | 0.66% |